Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

MEDI: First quarter 2025 financial results and status for Medistim ASA

Medistim
An exceptionally strong quarter for sales revenues, 20.1 % above the previous
record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter
last year (MNOK 133.8).

Currency neutral sales of own products were up 29.9 % for the quarter.

Strong growth in all geographies with AMERICAS up 28.4 %, EMEA up 18.2 % and
APAC up 62.6 %, currency neutral.

Third-party distributor sales in Scandinavia increased 41.2 % for the quarter.

Operating profit (EBIT) grew by 84.5 % and ended at MNOK 59.2 giving a 32.6 %
EBIT margin (MNOK 32.1, 24.0 % margin)

Recurring sales remained high, but strong capital sales reduce recurring sales
in percent to 68 % (75 %) compared to same quarter last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial
Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 183.4 and no interest-bearing
liabilities.
The General Meeting decided a dividend of NOK 6.00 per share (NOK 4.5), total
MNOK 109.6 (MNOK 82.4).
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.